Drugs were halted in trials not because of safety concerns
Gene Logic will work with H. Lundbeck to reposition some of the latter’s drug candidates. These compounds were discontinued or de-prioritized in clinical trials for reasons other than safety, according to the companies.
The drug repositioning agreement provides for milestones and royalties similar to those paid for development-stage in-licensing deals, discounted to account for Lundbeck’s contribution as the originator of the compound. Gene Logic retains the option to exclusively license any candidate for which Gene Logic identifies a potential new use and Lundbeck chooses not to pursue. In such a case Lundbeck will be payed success-based milestones and royalties.
